Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Antiphospholipid Syndrome
•
Systemic lupus erythematosus
•
Benign Hematology
•
Anticoagulation
•
Hospital Medicine
How would you approach a patient with SLE and catastrophic antiphospholipid antibody system that has not responded to heparin, steroids, and PLEX?
How do you decide amongst other therapies such as eculizumab, rituximab, cyclophosphamide, IVIg?
Related Questions
How would you work up splenomegaly and abdominal pain in a patient with primary antiphospholipid syndrome and a high + ANA, but no other serological or clinical SLE symptoms?
Can anti-cardiolipin or anti-beta-2 glycoprotein antibodies cause prolonged PTT in the absence of a lupus anticoagulant?
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
Do you hospitalize patients with newly diagnosed lupus nephritis and nephrotic syndrome if you are able to provide pulse steroids outpatient and follow them closely?
For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
How would you approach pursuing a kidney biopsy in a patient with suspected lupus nephritis who is on warfarin for antiphospholipid antibody syndrome?
How would you approach the evaluation and management of isolated vasculitis with aneurysms involving the segmental hepatic arteries causing hepatic hemorrhage in an otherwise healthy patient in his 80s?
Excluding CLL, in which patients would you screen for hypogammaglobulinemia?
How do you manage recalcitrant tumid lupus in a patient with partial response to antimalarials and off-label apremilast, in the setting of coexisting MDS with significant neutropenia?